Project Grant R21AR084252
Award Date
8/20/24
Completion Date
7/31/26
Dollars Obligated
$173K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Irvine, CA 92697, USA
Similar Awards
This $169,560 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research to characterize the cutaneous opioid circuitry and its role in regulating skin inflammation and sensation. The awardee, The Regents of the University of California, San Francisco, aims to identify the cellular sources of the endogenous opioid enkephalin and how it...
This $198,782 federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to enable the investigation of interactions between the skin microbiome and skin cell populations using genetically modified 3D in vitro models. The award will support the development of 3D reconstructed human epidermis (RHE) cultures with CRISPR/Cas9 knockouts in key skin...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $260,000.00 to the University of Chicago to investigate the mechanism of skin blistering caused by chemical warfare agents, specifically vesicants. The goal is to determine the role of the cytoskeletal protein ACF7 and the signaling molecule FAK in regulating cell adhesion...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $383,570 to Temple University to conduct research on interleukin-36 (IL-36) cytokine activation and inactivation mechanisms. The project aims to improve understanding of IL-36 functions and their role in inflammatory conditions, such as atopic dermatitis, psoriasis, and skin infections,...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) provides $295,294 to Biotherapeutics, Inc. for the development of a novel first-in-class topical immunoregulatory therapeutic for the treatment of plaque psoriasis. The key objectives are to: 1) evaluate the permeability and long-term stability of the topical drug product formulation, 2) compare the...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research to investigate the long-term systemic consequences of type 2 skin inflammation on epithelial stem cells. The $242,310 award to Rockefeller University will fund a 2.5-year study to define the specific cell-intrinsic mechanisms and niche signaling that underlie the...
This $664,933 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research into the cellular and molecular mechanisms of interleukin-17A (IL-17A) in the pathogenesis of psoriatic arthritis. The research aims to define the early cellular and molecular pathways that drive IL-17A-induced joint and skin inflammation, enthesitis, fingernail psoriasis,...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $673,729.00 to the University of Pittsburgh to define the impact of dietary conjugated linoleic acid (CLA) on the formation of nitro-fatty acids (NO2-FAs) in skin tissues, and establish the protective effects of endogenous NO2-CLA formation on the autoimmune skin condition psoriasis. The...
This $548,828 Project Grant was awarded on September 21, 2023 by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant was awarded to Knoubis Bio Inc., a for-profit organization based in California, to support research on a non-immunosuppressive disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis. The project aims to develop a new therapeutic approach...
This SBIR Phase I award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $295,924 to Biotherapeutics, Inc. to develop a novel topical therapeutic for the treatment of psoriasis. The key objectives are to: 1) characterize the therapeutic efficacy of the new treatment in a mouse model of psoriasis, 2) develop a topical drug product formulation and test its...